CN111094574B - 使用包括硫代磷酸酯化的核苷酸的双链多联体dna的体内rna或蛋白质表达 - Google Patents
使用包括硫代磷酸酯化的核苷酸的双链多联体dna的体内rna或蛋白质表达 Download PDFInfo
- Publication number
- CN111094574B CN111094574B CN201880060299.6A CN201880060299A CN111094574B CN 111094574 B CN111094574 B CN 111094574B CN 201880060299 A CN201880060299 A CN 201880060299A CN 111094574 B CN111094574 B CN 111094574B
- Authority
- CN
- China
- Prior art keywords
- dna
- nucleotides
- sequence
- double
- rca
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 125000003729 nucleotide group Chemical group 0.000 title claims abstract description 128
- 239000002773 nucleotide Substances 0.000 title claims abstract description 123
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 86
- 102000004169 proteins and genes Human genes 0.000 title claims abstract description 72
- 108091028732 Concatemer Proteins 0.000 title claims abstract description 70
- 238000001727 in vivo Methods 0.000 title abstract description 39
- 238000000034 method Methods 0.000 claims abstract description 33
- 210000003527 eukaryotic cell Anatomy 0.000 claims abstract description 21
- 108091081062 Repeated sequence (DNA) Proteins 0.000 claims abstract description 15
- 108020004414 DNA Proteins 0.000 claims description 225
- 239000013612 plasmid Substances 0.000 claims description 66
- 210000004027 cell Anatomy 0.000 claims description 61
- 108700026244 Open Reading Frames Proteins 0.000 claims description 40
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 38
- 238000001890 transfection Methods 0.000 claims description 32
- 108091026890 Coding region Proteins 0.000 claims description 31
- 238000013519 translation Methods 0.000 claims description 31
- 230000003321 amplification Effects 0.000 claims description 30
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 30
- 150000007523 nucleic acids Chemical class 0.000 claims description 21
- 102000039446 nucleic acids Human genes 0.000 claims description 17
- 108020004707 nucleic acids Proteins 0.000 claims description 17
- 108020004705 Codon Proteins 0.000 claims description 15
- 108091093037 Peptide nucleic acid Proteins 0.000 claims description 12
- 238000000746 purification Methods 0.000 claims description 11
- 108020004684 Internal Ribosome Entry Sites Proteins 0.000 claims description 10
- 230000001404 mediated effect Effects 0.000 claims description 10
- 239000004055 small Interfering RNA Substances 0.000 claims description 10
- 230000005030 transcription termination Effects 0.000 claims description 10
- 230000004927 fusion Effects 0.000 claims description 7
- 239000012212 insulator Substances 0.000 claims description 7
- 238000000338 in vitro Methods 0.000 claims description 6
- NOLHIMIFXOBLFF-KVQBGUIXSA-N (2r,3s,5r)-5-(2,6-diaminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-ol Chemical compound C12=NC(N)=NC(N)=C2N=CN1[C@H]1C[C@H](O)[C@@H](CO)O1 NOLHIMIFXOBLFF-KVQBGUIXSA-N 0.000 claims description 5
- PISWNSOQFZRVJK-XLPZGREQSA-N 1-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-methyl-2-sulfanylidenepyrimidin-4-one Chemical compound S=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 PISWNSOQFZRVJK-XLPZGREQSA-N 0.000 claims description 5
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 claims description 5
- 229930010555 Inosine Natural products 0.000 claims description 5
- 230000002708 enhancing effect Effects 0.000 claims description 5
- 229960003786 inosine Drugs 0.000 claims description 5
- 108091027967 Small hairpin RNA Proteins 0.000 claims description 4
- 108020004459 Small interfering RNA Proteins 0.000 claims description 4
- 108020004566 Transfer RNA Proteins 0.000 claims description 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 4
- 108020004418 ribosomal RNA Proteins 0.000 claims description 4
- 210000004962 mammalian cell Anatomy 0.000 claims description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 3
- 108020005544 Antisense RNA Proteins 0.000 claims description 2
- 108091079001 CRISPR RNA Proteins 0.000 claims description 2
- 241000238631 Hexapoda Species 0.000 claims description 2
- 239000001506 calcium phosphate Substances 0.000 claims description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 claims description 2
- 235000011010 calcium phosphates Nutrition 0.000 claims description 2
- 229920006317 cationic polymer Polymers 0.000 claims description 2
- 239000003184 complementary RNA Substances 0.000 claims description 2
- 238000004520 electroporation Methods 0.000 claims description 2
- 238000001476 gene delivery Methods 0.000 claims description 2
- 239000002502 liposome Substances 0.000 claims description 2
- 239000002105 nanoparticle Substances 0.000 claims description 2
- 230000003287 optical effect Effects 0.000 claims description 2
- 230000035939 shock Effects 0.000 claims description 2
- 238000010361 transduction Methods 0.000 claims description 2
- 230000026683 transduction Effects 0.000 claims description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 claims description 2
- 210000005253 yeast cell Anatomy 0.000 claims description 2
- 108091070501 miRNA Proteins 0.000 claims 3
- 230000014616 translation Effects 0.000 description 33
- 108010054624 red fluorescent protein Proteins 0.000 description 28
- 238000006243 chemical reaction Methods 0.000 description 26
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 24
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 24
- 239000005090 green fluorescent protein Substances 0.000 description 24
- 239000000203 mixture Substances 0.000 description 20
- 238000004519 manufacturing process Methods 0.000 description 14
- 238000005096 rolling process Methods 0.000 description 13
- 108091028043 Nucleic acid sequence Proteins 0.000 description 12
- 238000003776 cleavage reaction Methods 0.000 description 11
- 239000002609 medium Substances 0.000 description 10
- 101710154606 Hemagglutinin Proteins 0.000 description 9
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 9
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 9
- 101710176177 Protein A56 Proteins 0.000 description 9
- 230000029087 digestion Effects 0.000 description 9
- 230000001965 increasing effect Effects 0.000 description 9
- 108020004999 messenger RNA Proteins 0.000 description 9
- 230000007017 scission Effects 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 8
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 8
- 230000027455 binding Effects 0.000 description 8
- SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 8
- SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 8
- 239000000185 hemagglutinin Substances 0.000 description 8
- 230000035897 transcription Effects 0.000 description 8
- 238000013518 transcription Methods 0.000 description 8
- 108091005804 Peptidases Proteins 0.000 description 7
- 239000004365 Protease Substances 0.000 description 7
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 7
- 239000003153 chemical reaction reagent Substances 0.000 description 6
- 238000012545 processing Methods 0.000 description 6
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 6
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 5
- 108700010070 Codon Usage Proteins 0.000 description 5
- 102000053602 DNA Human genes 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 5
- 229930182816 L-glutamine Natural products 0.000 description 5
- 239000012097 Lipofectamine 2000 Substances 0.000 description 5
- 101710163270 Nuclease Proteins 0.000 description 5
- 108091034117 Oligonucleotide Proteins 0.000 description 5
- 239000007983 Tris buffer Substances 0.000 description 5
- 229940088598 enzyme Drugs 0.000 description 5
- 108010052305 exodeoxyribonuclease III Proteins 0.000 description 5
- 239000012091 fetal bovine serum Substances 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- 239000011541 reaction mixture Substances 0.000 description 5
- 239000012679 serum free medium Substances 0.000 description 5
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 5
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 4
- 230000004544 DNA amplification Effects 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 108060002716 Exonuclease Proteins 0.000 description 4
- 239000007995 HEPES buffer Substances 0.000 description 4
- 239000012981 Hank's balanced salt solution Substances 0.000 description 4
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 4
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 4
- HAAZLUGHYHWQIW-KVQBGUIXSA-N dGTP Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 description 4
- NHVNXKFIZYSCEB-XLPZGREQSA-N dTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 NHVNXKFIZYSCEB-XLPZGREQSA-N 0.000 description 4
- 238000004925 denaturation Methods 0.000 description 4
- 230000036425 denaturation Effects 0.000 description 4
- 102000013165 exonuclease Human genes 0.000 description 4
- 238000000684 flow cytometry Methods 0.000 description 4
- 239000000017 hydrogel Substances 0.000 description 4
- 239000013600 plasmid vector Substances 0.000 description 4
- 230000014621 translational initiation Effects 0.000 description 4
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 108010007577 Exodeoxyribonuclease I Proteins 0.000 description 3
- 108700011259 MicroRNAs Proteins 0.000 description 3
- 229930182555 Penicillin Natural products 0.000 description 3
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 238000000246 agarose gel electrophoresis Methods 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 230000002255 enzymatic effect Effects 0.000 description 3
- 238000006911 enzymatic reaction Methods 0.000 description 3
- 239000013613 expression plasmid Substances 0.000 description 3
- 229960002743 glutamine Drugs 0.000 description 3
- 206010022000 influenza Diseases 0.000 description 3
- 239000002679 microRNA Substances 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000005457 optimization Methods 0.000 description 3
- 229940049954 penicillin Drugs 0.000 description 3
- 229960005322 streptomycin Drugs 0.000 description 3
- 125000000446 sulfanediyl group Chemical group *S* 0.000 description 3
- 108020004638 Circular DNA Proteins 0.000 description 2
- 102000012410 DNA Ligases Human genes 0.000 description 2
- 108010061982 DNA Ligases Proteins 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 2
- 102000003960 Ligases Human genes 0.000 description 2
- 108090000364 Ligases Proteins 0.000 description 2
- 108091007412 Piwi-interacting RNA Proteins 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 101710176276 SSB protein Proteins 0.000 description 2
- 108020004682 Single-Stranded DNA Proteins 0.000 description 2
- 101710126859 Single-stranded DNA-binding protein Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- PZBFGYYEXUXCOF-UHFFFAOYSA-N TCEP Chemical compound OC(=O)CCP(CCC(O)=O)CCC(O)=O PZBFGYYEXUXCOF-UHFFFAOYSA-N 0.000 description 2
- 238000001261 affinity purification Methods 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 238000012197 amplification kit Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 150000001768 cations Chemical class 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000005484 gravity Effects 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 2
- 229920002704 polyhistidine Polymers 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- -1 procaryotes Proteins 0.000 description 2
- 238000001243 protein synthesis Methods 0.000 description 2
- 239000011535 reaction buffer Substances 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 238000007363 ring formation reaction Methods 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 2
- 230000001052 transient effect Effects 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 1
- 108020003589 5' Untranslated Regions Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 108091033409 CRISPR Proteins 0.000 description 1
- 238000010354 CRISPR gene editing Methods 0.000 description 1
- 108091035707 Consensus sequence Proteins 0.000 description 1
- 102000052510 DNA-Binding Proteins Human genes 0.000 description 1
- 101710116602 DNA-Binding protein G5P Proteins 0.000 description 1
- 108010013369 Enteropeptidase Proteins 0.000 description 1
- 102100029727 Enteropeptidase Human genes 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 102100029075 Exonuclease 1 Human genes 0.000 description 1
- XZWYTXMRWQJBGX-VXBMVYAYSA-N FLAG peptide Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@@H](N)CC(O)=O)CC1=CC=C(O)C=C1 XZWYTXMRWQJBGX-VXBMVYAYSA-N 0.000 description 1
- 101150066002 GFP gene Proteins 0.000 description 1
- 108700007698 Genetic Terminator Regions Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102000005720 Glutathione transferase Human genes 0.000 description 1
- 108010070675 Glutathione transferase Proteins 0.000 description 1
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 108020005004 Guide RNA Proteins 0.000 description 1
- 206010069767 H1N1 influenza Diseases 0.000 description 1
- 101150039660 HA gene Proteins 0.000 description 1
- 241000701024 Human betaherpesvirus 5 Species 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 102000017143 RNA Polymerase I Human genes 0.000 description 1
- 108010013845 RNA Polymerase I Proteins 0.000 description 1
- 102000014450 RNA Polymerase III Human genes 0.000 description 1
- 108010078067 RNA Polymerase III Proteins 0.000 description 1
- 102000018120 Recombinases Human genes 0.000 description 1
- 108010091086 Recombinases Proteins 0.000 description 1
- 101710162453 Replication factor A Proteins 0.000 description 1
- 101710176758 Replication protein A 70 kDa DNA-binding subunit Proteins 0.000 description 1
- 108091027544 Subgenomic mRNA Proteins 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 101710137500 T7 RNA polymerase Proteins 0.000 description 1
- 108010017842 Telomerase Proteins 0.000 description 1
- 108020005038 Terminator Codon Proteins 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical group OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- 108091028113 Trans-activating crRNA Proteins 0.000 description 1
- 102000008579 Transposases Human genes 0.000 description 1
- 108010020764 Transposases Proteins 0.000 description 1
- 210000001766 X chromosome Anatomy 0.000 description 1
- 108091007416 X-inactive specific transcript Proteins 0.000 description 1
- 108091035715 XIST (gene) Proteins 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- CCPIKNHZOWQALM-DLQJRSQOSA-N [[(2r,3s,5r)-5-(6-aminopurin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphinothioyl] phosphono hydrogen phosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=S)OP(O)(=O)OP(O)(O)=O)O1 CCPIKNHZOWQALM-DLQJRSQOSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 238000007259 addition reaction Methods 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000012443 analytical study Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- OSQPUMRCKZAIOZ-UHFFFAOYSA-N carbon dioxide;ethanol Chemical compound CCO.O=C=O OSQPUMRCKZAIOZ-UHFFFAOYSA-N 0.000 description 1
- 101150038500 cas9 gene Proteins 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000003508 chemical denaturation Methods 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 101150027692 exoI gene Proteins 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 208000037797 influenza A Diseases 0.000 description 1
- 229940033326 influenza DNA vaccine Drugs 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 229940065638 intron a Drugs 0.000 description 1
- 238000013493 large scale plasmid preparation Methods 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 108700024542 myc Genes Proteins 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 125000003835 nucleoside group Chemical group 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical group 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 230000001124 posttranscriptional effect Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000013615 primer Substances 0.000 description 1
- 239000002987 primer (paints) Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001915 proofreading effect Effects 0.000 description 1
- 230000012846 protein folding Effects 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000012429 reaction media Substances 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000010008 shearing Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 210000001324 spliceosome Anatomy 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 238000003153 stable transfection Methods 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- 201000010740 swine influenza Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 108010057210 telomerase RNA Proteins 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000003146 transient transfection Methods 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- A61K48/0066—Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/67—General methods for enhancing the expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2531/00—Reactions of nucleic acids characterised by
- C12Q2531/10—Reactions of nucleic acids characterised by the purpose being amplify/increase the copy number of target nucleic acid
- C12Q2531/125—Rolling circle
Landscapes
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims (20)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15/707,074 US10350307B2 (en) | 2017-09-18 | 2017-09-18 | In vivo RNA or protein expression using double-stranded concatemeric DNA including phosphorothioated nucleotides |
US15/707074 | 2017-09-18 | ||
PCT/EP2018/074559 WO2019053039A1 (en) | 2017-09-18 | 2018-09-12 | EXPRESSION OF IN VIVO RNA OR PROTEIN USING DOUBLE-STRANDED CONCATEMARY DNA COMPRISING PHOSPHOROTHIOATE NUCLEOTIDES |
Publications (2)
Publication Number | Publication Date |
---|---|
CN111094574A CN111094574A (zh) | 2020-05-01 |
CN111094574B true CN111094574B (zh) | 2024-04-16 |
Family
ID=63685930
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201880060299.6A Active CN111094574B (zh) | 2017-09-18 | 2018-09-12 | 使用包括硫代磷酸酯化的核苷酸的双链多联体dna的体内rna或蛋白质表达 |
Country Status (6)
Country | Link |
---|---|
US (1) | US10350307B2 (zh) |
EP (1) | EP3684934A1 (zh) |
JP (1) | JP7209700B2 (zh) |
KR (1) | KR102664627B1 (zh) |
CN (1) | CN111094574B (zh) |
WO (1) | WO2019053039A1 (zh) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10077459B2 (en) | 2016-05-04 | 2018-09-18 | General Electric Company | Cell-free protein expression using rolling circle amplification product |
US20200392554A1 (en) * | 2019-06-13 | 2020-12-17 | General Electric Company | Expression of products from nucleic acid concatemers |
EP4083227A1 (en) | 2021-04-29 | 2022-11-02 | 4basebio, S.L.U. | Linear dna with enhanced resistance against exonucleases |
EP4310182A1 (en) * | 2022-07-19 | 2024-01-24 | 4basebio UK Ltd | Protected dna and methods for the production thereof |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6316229B1 (en) * | 1998-07-20 | 2001-11-13 | Yale University | Single molecule analysis target-mediated ligation of bipartite primers |
WO2005030983A2 (en) * | 2003-09-26 | 2005-04-07 | Circleamp, Inc. | Amplification of polynucleotides by rolling circle amplification |
JP2011527570A (ja) * | 2008-07-09 | 2011-11-04 | ゼネラル・エレクトリック・カンパニイ | 未処理rca産物 |
CN103080337A (zh) * | 2010-08-04 | 2013-05-01 | 触光基因学有限公司 | 利用回文序列生产闭合线性dna |
CN104583413A (zh) * | 2012-06-29 | 2015-04-29 | 通用电气公司 | 用于自rna模板开始的等温dna扩增试剂盒 |
CN104946737A (zh) * | 2013-12-11 | 2015-09-30 | 阿卡拉根公司 | 用于检测罕见序列变体的组合物和方法 |
CN105283588A (zh) * | 2013-02-26 | 2016-01-27 | 艾希奥美公司 | 用于产生用于定向进化的文库的方法 |
CN106460058A (zh) * | 2014-03-30 | 2017-02-22 | 赛沛 | 经修饰的胞嘧啶多核苷酸寡聚物和方法 |
CN106661631A (zh) * | 2014-06-06 | 2017-05-10 | 康奈尔大学 | 使用组合的核酸酶、连接酶、聚合酶和测序反应识别和枚举核酸序列、表达、拷贝或dna甲基化变化的方法 |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5030566A (en) * | 1989-01-04 | 1991-07-09 | Board Of Regents, The University Of Texas System | Concatemeric DNA length standards |
US5854033A (en) * | 1995-11-21 | 1998-12-29 | Yale University | Rolling circle replication reporter systems |
JP2003517428A (ja) * | 1997-09-17 | 2003-05-27 | イースト カロライナ ユニバーシティ | 複数標的ハイブリダイゼーション用核酸、その調製、組成物、製剤、キット及び応用 |
US6323009B1 (en) | 2000-06-28 | 2001-11-27 | Molecular Staging, Inc. | Multiply-primed amplification of nucleic acid sequences |
US8361712B2 (en) | 2007-12-17 | 2013-01-29 | General Electric Company | Contamination-free reagents for nucleic acid amplification |
DE10342373A1 (de) * | 2003-09-14 | 2005-04-07 | Noxxon Pharma Ag | Verfahren zur Synthese von Nukleinsäuren und deren Anwendung |
WO2006063355A2 (en) | 2004-12-11 | 2006-06-15 | Cytogenix , Inc. | Cell free biosynthesis of high-quality nucleic acid and uses thereof |
US9125845B2 (en) | 2008-07-09 | 2015-09-08 | General Electric Company | DNA vaccines, uses for unprocessed rolling circle amplification product and methods for making the same |
US8921072B2 (en) | 2008-09-02 | 2014-12-30 | General Electric Compnay | Methods to generate DNA mini-circles |
WO2011012316A2 (de) * | 2009-07-31 | 2011-02-03 | Ludwig-Maximilians-Universität | Rna mit einer kombination aus unmodifizierten und modifizierten nucleotiden zur proteinexpression |
US9545421B2 (en) | 2010-05-04 | 2017-01-17 | General Electric Company | Nucleic acid delivery vehicle and uses thereof |
SG192869A1 (en) * | 2011-02-24 | 2013-09-30 | Pharmaxis Ltd | Oligonucleotide inhibitors with chimeric backbone and 2-amino-2'-deoxyadenosine |
SG10201801428RA (en) * | 2013-08-21 | 2018-03-28 | Curevac Ag | Method for increasing expression of rna-encoded proteins |
EP3041938A1 (en) * | 2013-09-03 | 2016-07-13 | Moderna Therapeutics, Inc. | Circular polynucleotides |
US10179932B2 (en) * | 2014-07-11 | 2019-01-15 | President And Fellows Of Harvard College | Methods for high-throughput labelling and detection of biological features in situ using microscopy |
CN108431228A (zh) * | 2015-12-25 | 2018-08-21 | Sbi生物技术有限公司 | Tlr抑制性寡核苷酸及其用途 |
US10077459B2 (en) * | 2016-05-04 | 2018-09-18 | General Electric Company | Cell-free protein expression using rolling circle amplification product |
US11834670B2 (en) * | 2017-04-19 | 2023-12-05 | Global Life Sciences Solutions Usa Llc | Site-specific DNA modification using a donor DNA repair template having tandem repeat sequences |
-
2017
- 2017-09-18 US US15/707,074 patent/US10350307B2/en active Active
-
2018
- 2018-09-12 KR KR1020207007766A patent/KR102664627B1/ko active IP Right Grant
- 2018-09-12 EP EP18778820.3A patent/EP3684934A1/en active Pending
- 2018-09-12 CN CN201880060299.6A patent/CN111094574B/zh active Active
- 2018-09-12 JP JP2020515982A patent/JP7209700B2/ja active Active
- 2018-09-12 WO PCT/EP2018/074559 patent/WO2019053039A1/en unknown
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6316229B1 (en) * | 1998-07-20 | 2001-11-13 | Yale University | Single molecule analysis target-mediated ligation of bipartite primers |
WO2005030983A2 (en) * | 2003-09-26 | 2005-04-07 | Circleamp, Inc. | Amplification of polynucleotides by rolling circle amplification |
JP2011527570A (ja) * | 2008-07-09 | 2011-11-04 | ゼネラル・エレクトリック・カンパニイ | 未処理rca産物 |
CN103080337A (zh) * | 2010-08-04 | 2013-05-01 | 触光基因学有限公司 | 利用回文序列生产闭合线性dna |
CN104583413A (zh) * | 2012-06-29 | 2015-04-29 | 通用电气公司 | 用于自rna模板开始的等温dna扩增试剂盒 |
CN105283588A (zh) * | 2013-02-26 | 2016-01-27 | 艾希奥美公司 | 用于产生用于定向进化的文库的方法 |
CN104946737A (zh) * | 2013-12-11 | 2015-09-30 | 阿卡拉根公司 | 用于检测罕见序列变体的组合物和方法 |
CN106460058A (zh) * | 2014-03-30 | 2017-02-22 | 赛沛 | 经修饰的胞嘧啶多核苷酸寡聚物和方法 |
CN106661631A (zh) * | 2014-06-06 | 2017-05-10 | 康奈尔大学 | 使用组合的核酸酶、连接酶、聚合酶和测序反应识别和枚举核酸序列、表达、拷贝或dna甲基化变化的方法 |
Non-Patent Citations (3)
Title |
---|
Alexandre Berr等.Direct labelling of BAC-DNA by rolling-circle amplification.Plant J.2006,全文. * |
Rui Gan等.DNA phosphorothioate modifications influence the global transcriptional response and protect DNA from double-stranded breaks.Science reports.2014,第4卷(第4期),摘要. * |
李生.基于Phi29DNA聚合酶和Cre重组酶的环状DNA分子等温扩增.中国优秀硕士学位论文全文数据库 基础科学辑.2018,全文. * |
Also Published As
Publication number | Publication date |
---|---|
EP3684934A1 (en) | 2020-07-29 |
KR102664627B1 (ko) | 2024-05-10 |
JP7209700B2 (ja) | 2023-01-20 |
JP2020537505A (ja) | 2020-12-24 |
WO2019053039A1 (en) | 2019-03-21 |
CN111094574A (zh) | 2020-05-01 |
US20190083655A1 (en) | 2019-03-21 |
US10350307B2 (en) | 2019-07-16 |
KR20200051648A (ko) | 2020-05-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN111094574B (zh) | 使用包括硫代磷酸酯化的核苷酸的双链多联体dna的体内rna或蛋白质表达 | |
CN111819185A (zh) | 包含环状多核糖核苷酸的组合物及其用途 | |
JP7292258B2 (ja) | 縦列反復配列を有するドナーdna修復鋳型を使用する部位特異的なdna改変 | |
JP7058839B2 (ja) | ローリングサークル増幅産物を使用した無細胞タンパク質発現 | |
CN113661242A (zh) | 包含经修饰的环状多核糖核苷酸的组合物及其用途 | |
JP2004524031A (ja) | 合成遺伝子、およびCpGを欠く細菌プラスミド | |
EP2307575B1 (en) | Unprocessed rolling circle amplification product | |
CA3114892A1 (en) | Methods and compositions for increasing capping efficiency of transcribed rna | |
EP4159853A1 (en) | Genome editing system and method | |
KR102664617B1 (ko) | 이중-가닥 콘카테머 dna를 사용하는 무세포 단백질 발현 | |
CN115397982A (zh) | 核酸组合物 | |
EP4219723A1 (en) | Circular rna platforms, uses thereof, and their manufacturing processes from engineered dna | |
CA2555489C (en) | Method of converting base in dna sequence | |
WO2024039652A1 (en) | Cell-free method of producing synthetic circular nucleic acid | |
KR20240055811A (ko) | 프라임 편집을 위한 화학적 변형을 갖는 가이드 rna | |
AU2020356441A1 (en) | A nucleic acid delivery vector comprising a circular single stranded polynucleotide |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20210809 Address after: England Applicant after: Global life science solutions UK Ltd. Address before: Buckinghamshire Applicant before: GE HEALTHCARE UK Ltd. Effective date of registration: 20210809 Address after: Buckinghamshire Applicant after: GE HEALTHCARE UK Ltd. Address before: New York State, USA Applicant before: General Electric Co. |
|
TA01 | Transfer of patent application right | ||
GR01 | Patent grant | ||
GR01 | Patent grant |